BMC infectious diseases · 2026
Immunogenicity and safety of novel oral polio vaccine type 2 (nOPV2) in pediatric populations: a systematic review and Bayesian meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boene José Luís, Campos Letícia Rocha, Carpi Gisella Chiara, Muhawenimana Monica, Machado Sandra Helena, de Deus Nilsa, Bauhofer Adilson Fernando Loforte
Аннотация
BACKGROUND: Following the 2016 global cessation of oral poliovirus vaccine type 2, outbreaks of circulating vaccine-derived poliovirus type 2 have posed significant public health challenges. The novel oral poliovirus vaccine type 2 (nOPV2), developed for enhanced genetic stability, lacks comprehensive pediatric data.
OBJECTIVE: To systematically evaluate nOPV2 immunogenicity and safety in under-immunized pediatric populations through Bayesian meta-analysis.
METHODS: We searched five databases from 2015 to 2025 for RCTs and observational studies of nOPV2 in children under 18 years from under-immunized populations. Bayesian single-arm meta-analyses were performed.
RESULTS: Five studies (four RCTs, one cohort) with 10,421 children from Bangladesh, The Gambia, and the Dominican Republic were included. Pooled seroconversion rates ranged from 65.8% to 81.5%. Severe adverse events after nOPV2 vaccination yielded a pooled proportion of 0.01 (95% CI: 0.00-0.02), mild events occurred in 7.8%, and viral shedding was 64.7%.
CONCLUSIONS: nOPV2 shows robust immunogenicity and excellent safety, supporting its role in outbreak control and global polio eradication.
CLINICAL TRIAL NUMBER: Not applicable.
OBJECTIVE: To systematically evaluate nOPV2 immunogenicity and safety in under-immunized pediatric populations through Bayesian meta-analysis.
METHODS: We searched five databases from 2015 to 2025 for RCTs and observational studies of nOPV2 in children under 18 years from under-immunized populations. Bayesian single-arm meta-analyses were performed.
RESULTS: Five studies (four RCTs, one cohort) with 10,421 children from Bangladesh, The Gambia, and the Dominican Republic were included. Pooled seroconversion rates ranged from 65.8% to 81.5%. Severe adverse events after nOPV2 vaccination yielded a pooled proportion of 0.01 (95% CI: 0.00-0.02), mild events occurred in 7.8%, and viral shedding was 64.7%.
CONCLUSIONS: nOPV2 shows robust immunogenicity and excellent safety, supporting its role in outbreak control and global polio eradication.
CLINICAL TRIAL NUMBER: Not applicable.